TITLE

Trial Protocol: Communicating DNA-based risk assessments for Crohn's disease: a randomised controlled trial assessing impact upon stopping smoking

AUTHOR(S)
Whitwell, Sophia C. L.; Mathew, Christopher G.; Lewis, Cathryn M.; Forbes, Alastair; Watts, Sally; Sanderson, Jeremy; Hollands, Gareth J.; Prevost, A. Toby; Armstrong, David; Kinmonth, Ann Louise; Sutton, Stephen; Marteau, Theresa M.
PUB. DATE
January 2011
SOURCE
BMC Public Health;2011, Vol. 11 Issue 1, p44
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Estimates of the risk of developing Crohn's disease (CD) can be made using DNA testing for mutations in the NOD2 (CARD15) gene, family history, and smoking status. Smoking doubles the risk of CD, a risk that is reduced by stopping. CD therefore serves as a timely and novel paradigm within which to assess the utility of predictive genetic testing to motivate behaviour change to reduce the risk of disease. The aim of the study is to describe the impact upon stopping smoking of communicating a risk of developing CD that incorporates DNA analysis. We will test the following main hypothesis: Smokers who are first degree relatives (FDRs) of CD probands are more likely to make smoking cessation attempts following communication of risk estimates of developing CD that incorporate DNA analysis, compared with an equivalent communication that does not incorporate DNA analysis. Methods/design: A parallel groups randomised controlled trial in which smokers who are FDRs of probands with CD are randomly allocated in families to undergo one of two types of assessment of risk for developing CD based on either: i. DNA analysis, family history of CD and smoking status, or ii. Family history of CD and smoking status The primary outcome is stopping smoking for 24 hours or longer in the six months following provision of risk information. The secondary outcomes are seven-day smoking abstinence at one week and six month follow-ups. Randomisation of 470 smoking FDRs of CD probands, with 400 followed up (85%), provides 80% power to detect a difference in the primary outcome of 14% between randomised arms, at the 5% significance level. Discussion: This trial provides one of the strongest tests to date of the impact of communicating DNA-based risk assessment on risk-reducing behaviour change. Specific issues regarding the choice of trial design are discussed. Trial Registration: ISRCTN: ISRCTN21633644.
ACCESSION #
59162570

 

Related Articles

  • Analysis of mutations in TP53, APC, K-ras, and DCC genes in the non-dysplastic mucosa of patients with inflammatory bowel disease. Rapozo, Davy Carlos Mendes; Grinmann, Ana Braunstein; Carvalho, Ana Teresa Pugas; de Souza, Heitor Siffert P.; Soares-Lima, Sheila Coelho; Simão, Tatiana de Almeida; de Paiva, Daurita; Abby, Flávio; Albano, Rodolpho Mattos; Pinto, Luiz Felipe Ribeiro // International Journal of Colorectal Disease;Oct2009, Vol. 24 Issue 10, p1141 

    Patients with ulcerative colitis (UC) and Crohn's disease (CD) have a high risk for colorectal cancer (CRC). To understand the molecular basis of colitis-associated CRC, we analyzed alterations in TP53, APC, K-ras, and DCC genes in the non-dysplastic UC and CD colon. Endoscopic biopsies were...

  • NOD2 mutations and Crohn's disease: are Paneth cells and their antimicrobial peptides the link? Grimm, M. C.; Pavli, P. // Gut;Nov2004, Vol. 53 Issue 11, p1558 

    The article examines if there is an association of Paneth cells and their antimicrobial peptides in NOD2 mutations and Crohn's disease. According to the authors, there is manifestation that NOD2 variants in Crohn's disease are associated with atrophied mucosal Α-defensin production, leading...

  • A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Ogura, Yasunori; Bonen, Denise K.; Inohara, Naohiro; Nicolae, Dan L.; Chen, Felicia F.; Ramos, Richard; Britton, Heidi; Moran, Thomas; Karaliuskas, Reda; Duerr, Richard H.; Achkar, Jean-Paul; Brant, Steven R.; Bayless, Theodore M.; Kirschner, Barbara S.; Hanauer, Stephen B.; Nunez, Gabriel; Cho, Judy H. // Nature;5/31/2001, Vol. 411 Issue 6837, p603 

    Presents a study which determined the association of a frameshift mutation in NOD2 caused by a cytosine insertion with Crohn's disease. Background on the idiopathic inflammatory bowel diseases; Methods used; Findings of the study.

  • Effect of communicating DNA based risk assessments for Crohn's disease on smoking cessation: randomised controlled trial.  // Inflammatory Bowel Disease Monitor;2012, Vol. 13 Issue 2, p74 

    This randomized controlled study investigated whether prior knowledge of genetic risk for Crohn's disease can influence a modifiable behavioral risk factor, namely smoking, in individuals with a family history of Crohn's disease.

  • Inflammatory Bowel Disease. Abraham, Clara; Cho, Judy H. // New England Journal of Medicine;11/19/2009, Vol. 361 Issue 21, p2066 

    The article offers information on the medical condition known as the inflammatory bowel disease. Several treatment options for this condition are cited such as lifestyle alteration like smoking cessation for those who are suffering from Chron's disease a well as surgical interventions. The...

  • Possible Exacerbation of Crohn's Disease Caused By Varenicline. Rowland, Martin; Koenigsfeld, Carrie Foust; Wall, Geoffrey C. // Journal of Smoking Cessation;Apr2008, Vol. 3 Issue 1, p63 

    Purpose: To report a case of an increase in Crohn's disease (CD) activity possibly caused by varenicline. Background: Smoking cigarettes has been shown to be an independent risk factor for the development of CD and is associated with a more aggressive disease course. Smoking cessation is...

  • A Prospective Study of Cigarette Smoking and the Risk of Inflammatory Bowel Disease in Women. Higuchi, Leslie M; Khalili, Hamed; Chan, Andrew T; Richter, James M; Bousvaros, Athos; Fuchs, Charles S // American Journal of Gastroenterology;Sep2012, Vol. 107 Issue 9, p1399 

    OBJECTIVES:Long-term data on the influence of cigarette smoking, especially cessation, on the risk of Crohn's disease (CD) and ulcerative colitis (UC) are limited.METHODS:We conducted a prospective study of 229,111 women in the Nurses' Health Study (NHS) and Nurses' Health Study II (NHS II)....

  • NOD2 Mutations Affect Muramyl Dipeptide Stimulation of Human B Lymphocytes and Interact with Other IBD-Associated Genes. Lin, Zhenwu; Hegarty, John; John, Gerrit; Berg, Arthur; Wang, Zhong; Sehgal, Rishabh; Pastor, Danielle; Wang, Yunhua; Harris, Leonard; Poritz, Lisa; Schreiber, Stefan; Koltun, Walter // Digestive Diseases & Sciences;Sep2013, Vol. 58 Issue 9, p2599 

    Background: Genetic and functional studies have associated variants in the NOD2/CARD15 gene with Crohn's disease. Aims: This study aims to replicate the association of three common NOD2 mutations with Crohn's disease, study its effect on NOD2 expression in B cells and its interaction with other...

  • They're bugs, Jim, but not as we know them.  // Gut;Sep2004, Vol. 53 Issue 9, p1385 

    The article discusses about various bacterial antigens that have been revealed in chronic inflammation in colitis and crohn's disease through pathogenesis. There is a relatively small number of immunodominant antigens that stimulate pathological T cell responses. Specific bacterial antigens...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics